Ergocalciferol
As of the edition of 20 October 2026, Ergocalciferol is a small molecule: marketed, first approved in 1982 (US); acts on VDR; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Drisdol
- First approved
- 1 January 1982 (US)
- Approvals on record
- 16 in 5 regions
- Holder of the most recent approval
- EURO-PHARM INTERNATIONAL CANADA INC; 10 holders in all
- Registered trials
- 446, 37 stopped early
- Disease areas
- Nutrition and metabolism; Bones, joints and muscles; Cancer; Hormones; Urinary and reproductive; Immune system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Ergocalciferol.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| VDR | Vitamin D3 receptor | P11473 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 205 | 130 | 29 | 11 |
| Phase 1 | 36 | 26 | 1 | 4 |
| Phase 2 | 59 | 38 | 4 | 9 |
| Phase 3 | 72 | 55 | 3 | 7 |
| Phase 4 | 74 | 50 | 4 | 6 |
| All trials | 446 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Esjay Pharma | Acquired holder | 2024 to now |
| Sanofi | Earlier holder |